HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.

Abstract
In previous research, we found α-enolase to be inversely correlated with progression-free and overall survival in lung cancer patients and detected α-enolase on the surface of lung cancer cells. Based on these findings, we hypothesized that surface α-enolase has a significant role in cancer metastasis and tested this hypothesis in the current study. We found that α-enolase was co-immunoprecipitated with urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen in lung cancer cells and interacted with these proteins in a cell-free dot blotting assay, which can be interrupted by α-enolase-specific antibody. α-Enolase in lung cancer cells co-localized with these proteins and was present at the site of pericellular degradation of extracellular matrix components. Treatment with antibody against α-enolase in vitro suppressed cell-associated plasminogen and matrix metalloproteinase activation, collagen and gelatin degradation, and cell invasion. Examination of the effect of treatment with shRNA plasmids revealed that down regulation of α-enolase decreases extracellular matrix degradation by and the invasion capacity of lung cancer cells. Adoptive transfer of α-enolase-specific antibody to mice resulted in accumulation of antibody in subcutaneous tumor and inhibited the formation of tumor metastasis in lung and bone. This study demonstrated that surface α-enolase promotes extracellular matrix degradation and invasion of cancer cells and that targeting surface α-enolase is a promising approach to suppress tumor metastasis.
AuthorsKuan-Chung Hsiao, Neng-Yao Shih, Hsun-Lang Fang, Tze-Sing Huang, Ching-Chuan Kuo, Pei-Yi Chu, Yi-Mei Hung, Shao-Wen Chou, Yi-Yuan Yang, Gee-Chen Chang, Ko-Jiunn Liu
JournalPloS one (PLoS One) Vol. 8 Issue 7 Pg. e69354 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID23894455 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Receptors, Urokinase Plasminogen Activator
  • Tumor Suppressor Proteins
  • Plasminogen
  • Urokinase-Type Plasminogen Activator
  • ENO1 protein, human
  • Phosphopyruvate Hydratase
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage, pharmacology)
  • Biomarkers, Tumor (antagonists & inhibitors, metabolism)
  • Bone Neoplasms (drug therapy, secondary)
  • Cell Line, Tumor
  • Cell Membrane (metabolism)
  • Cell Movement
  • DNA-Binding Proteins (antagonists & inhibitors, metabolism)
  • Extracellular Matrix (metabolism)
  • Humans
  • Immunocompromised Host
  • Lung Neoplasms (metabolism, mortality, pathology)
  • Male
  • Mice
  • Neoplasm Metastasis
  • Neoplasms (metabolism, mortality, pathology)
  • Phosphopyruvate Hydratase (antagonists & inhibitors, metabolism)
  • Plasminogen (metabolism)
  • Protein Binding
  • Receptors, Urokinase Plasminogen Activator (metabolism)
  • Tumor Suppressor Proteins (antagonists & inhibitors, metabolism)
  • Urokinase-Type Plasminogen Activator (metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: